Editorial
 NO SLA FOR KERALA AYUSH SECTOR!   
 Wednesday, April 18, 2018 
 The Rs 1000-crore ayurveda industry in Kerala is in total disarray, thanks largely to the egoistic attitude of the state government which has refused to reinstate Dr. N Vimala as State Licensing Authority (SLA) for Ayush 
  Past Editorial...  
TODAY'S NEWS
18:00  [IST]PhoenixMD inks manufacturing pact with WuXi STA
17:20  [IST]Healthcare experts see healthy liver, the key to normal body functioning
17:00  [IST]Akcea, Ionis complete licensing transaction to commercialize inotersen for hATTR
16:30  [IST]US FDA grants orphan drug designation to NeuroVive’s KL1333 to treat mitochondrial diseases
16:00  [IST]Bio-Techne expands RNAscope in situ hybridization automation to facilitate drug R&D
15:00  [IST]Sonoma Pharma receives four new UAE regulatory approvals for acne & anti-fungal products
more news >>
TOP NEWS
08:00  [IST]Uttarakhand DC suspends licences of 50 drug makers for manufacturing FDCs without DCGI approval
08:00  [IST]North eastern states defy odds to push MR vaccination drive forward; 7.72 crore kids immunised so far
08:00  [IST]AICTE modifies method of inspections in pharmacy colleges by making it jointly with universities & state govt
08:00  [IST]Investments to come in for pharma start-ups engaged in regulatory risk management & engagement beyond physician: Amit Mookim
08:00  [IST]Pharmexcil to conduct CoA elections on April 23 & 24,withdrawal of nominations on April 19, 2018
08:00  [IST]Ayush ministry tweaks norms to speed up permission process for opening Ayush medical colleges
more news >>
YESTERDAY'S NEWS
18:00  [IST]Yungjin Pharm completes recruitment in phase 1 single ascending dose study of KL1333
17:35  [IST]PregBuddy raises funds in seed round to advance its pregnancy application platform from IAN among others
17:20  [IST]Merck Foundation and Manipal Academy of Higher Education ink MoU to train embryologists from Africa and Asia
17:00  [IST]Researchers find Epstein-Barr virus protein can “switch on” risk genes for autoimmune diseases
16:30  [IST]Blueprint Medicines reports proof-of-concept data from phase 1 ARROW clinical trial of BLU-667 in patients with RET-altered solid tumor
16:00  [IST]US FDA approves Opdivo + Yervoy combo as first-line treatment for patients with intermediate- and poor-risk RCC
more news >>
INTERVIEW  
Indian Pharma Inc shifts to high gear in filing patents
Ruhan Rajput, Director, Einfolge.
Past Interviews...
 
  What's New?  
 
Opinion Poll
 
 
Will the central govt's decision to replace MCI with National Medical Commission boost the medical education scenario in the country?
 
 
 
   
 
  Corporate
Pharma Stocks
Executive Diary
Pharma People
Product Launches
  Special Features
Features
  Chronicle Pharmabiz Specials
Forthcoming
  Past
 
  Forthcoming Events
International
  Domestic
 
TENDERS & PROJECTS
Tenders & Enquiries
Pharma Projects
CORPORATE
Company Profile
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
US FDA UPDATE
US FDA: ANDA
US FDA: Warnings
US FDA: Approved NMEs
US FDA: New Approvals
EXPORT & IMPORT
Drug Export Procedures
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg. Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India
List of State Drugs Controllers
 
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |